Although this compound lacks specificity for PKC isoforms, it has served as a lead compound from which many other PKC inhibitors have been developed, among them, Midostaurin and Enzastaurin, which have been employed in anti-cancer clinical trials [174]. The gene discussed is PRRT2; the disease is cancer.